David T. Wong

From WikiProjectMed
Jump to navigation Jump to search

David T. Wong (born circa 1936 in Hong Kong) is a Hong Kong-born American neuroscientist. He is a former researcher with Eli Lilly and Company and an adjunct professor at the Indiana University School of Medicine. Wong is known for the discovery of the antidepressant drug fluoxetine, more commonly known by its trade name Prozac.[1][2][3]

Wong was born in Hong Kong, and began his undergraduate studies in chemistry at National Taiwan University. He came to Seattle Pacific College in 1957, and graduated in 1961. He then went on to graduate studies at Oregon State University, where he earned a master's degree in 1964 and later at University of Oregon to receive his doctorate in 1966. After doing his postdoctoral research at the University of Pennsylvania, he joined Eli Lilly in 1968.[1][2][3]

Compounds

While at Lilly, Wong became most interested in agents that bind to Biogenic Amine Transporters (BAT). These compounds primarily affect functioning of the CNS and have known uses in the treatment of depression, ADHD, libido, obesity and addiction. Although such agents can be made to increase serotonin and norepinephrine, an example of a compound with a demonstrated affinity for the DAT is called N-methylatmoxetine [83015-25-2].[4] He helped to study:

LY 125180
LY255582
  1. Fluoxetine
  2. Atomoxetine
  3. Duloxetine
  4. Dapoxetine,[3]
  5. Nisoxetine[5]
  6. LY 125180 [74515-39-2].[6]
  7. 6-CAT.[7]
  8. LY255582 [119193-09-8][8]
  9. LY278584 (tropane analog of Granisetron)[9]

Awards

  1. Wong won the Pharmaceutical Manufacturers Association Discoverer's Award in 1993.[1]
  2. Wong was named Alumnus of the Year by Seattle Pacific University in 1998.[2]
  3. He was given the Prince Mahidol Award in Medicine in 2011.[3]

Notes

  1. ^ a b c David T. Wong, Nature Reviews Drug Discovery, retrieved 2012-10-05.
  2. ^ a b c McDougall, Connie (Winter 1998), The Faith of a Scientist: Alumnus of the Year David T.Wong Devotes a Lifetime to Neuroscience Research, Seattle Pacific University.
  3. ^ a b c d "Scientist Who Developed Prozac Receives International Honor", Indiana University Medical School News, December 21, 2011, archived from the original on August 25, 2012.
  4. ^ Bryan B. Molloy & Klaus K. Schmiegel, U.S. patent 4,584,404 (1986 to Eli Lilly and Co).
  5. ^ Wong DT, Horng JS, Bymaster FP (September 1975). "dl-N-methyl-3-(o-methoxyphenoxy)-3-phenylpropylamine hydrochloride, Lilly 94939, a potent inhibitor for uptake of norepinephrine into rat brain synaptosomes and heart". Life Sciences. 17 (5): 755–760. doi:10.1016/0024-3205(75)90531-7. ISSN 0024-3205. PMID 1207394.
  6. ^ Wong DT, Bymaster FP, Chen S, Molloy BB (March 1980). "N, N-dimethyl-α-[2-(p-topoloxy) ethyl]benzylamine hydrochloride (LY125180)". Biochemical Pharmacology. 29 (6): 935–941. doi:10.1016/0006-2952(80)90224-5. ISSN 0006-2952. PMID 6966930.
  7. ^ Fuller RW, Wong DT, Snoddy HD, Bymaster FP (July 1977). "Comparison of the effects of 6-chloro-2-aminotetralin and of Org 6582, a related chloroamphetamine analog, on brain serotonin metabolism in rats". Biochemical Pharmacology. 26 (14): 1333–1337. doi:10.1016/0006-2952(77)90094-6. ISSN 0006-2952.
  8. ^ Mitch, C. H., Leander, J. D., Mendelsohn, L. G., Shaw, W. N., Wong, D. T., Cantrell, B. E., Johnson, B. G., Reel, J. K., Snoddy, J. D. (October 1993). "3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity". Journal of Medicinal Chemistry. 36 (20): 2842–2850. doi:10.1021/jm00072a002. eISSN 1520-4804. ISSN 0022-2623. PMID 8410999.
  9. ^ Wong, D. T., Robertson, D. W., Reid, L. R. (July 1989). "Specific [3H]LY278584 binding to 5-HT3 recognition sites in rat cerebral cortex". European Journal of Pharmacology. 166 (1): 107–110. doi:10.1016/0014-2999(89)90689-4. ISSN 0014-2999. PMID 2806363.
Retrieved from "https://mdwiki.org/wiki/David_T._Wong"